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Abstract
Background: Infants account for a small proportion of the overall dengue case burden in endemic countries but can be
clinically more difficult to manage. The clinical and laboratory features in infants with dengue have not been extensively
characterised.
Methodology/Principal Findings: This prospective, cross-sectional descriptive study of infants hospitalized with dengue
was conducted in Vietnam from November 2004 to December 2007. More than two-thirds of 303 infants enrolled on clinical
suspicion of dengue had a serologically confirmed dengue virus (DENV) infection. Almost all were primary dengue
infections and 80% of the infants developed DHF/DSS. At the time of presentation and during hospitalization, the clinical
signs and symptoms in infants with dengue were difficult to distinguish from those with other febrile illnesses, suggesting
that in infants early laboratory confirmation could assist appropriate management. Detection of plasma NS1 antigen was
found to be a sensitive marker of acute dengue in infants with primary infection, especially in the first few days of illness.
Conclusions/Significance: Collectively, these results provide a systematic description of the clinical features of dengue in
infants and highlight the value of NS1 detection for diagnosis.
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Introduction
Dengue represents a substantial disease burden in many tropical
and sub-tropical countries, particularly in children and young
adults [1]. Infection with any one of the four dengue virus (DENV)
serotypes can lead to a sub-clinical infection, or to clinical disease
ranging in severity from a non-specific febrile illness to classical
dengue fever, dengue hemorrhagic fever (DHF) and dengue shock
syndrome (DSS). Severe dengue (DHF/DSS) is strongly associated
with secondary heterotypic dengue virus infections in children and
adults [2,3], but can also occur in primary DENV infection of
infants born to dengue-immune mothers [4,5]. Common to these
two epidemiological populations are pre-existing DENV-reactive
IgG antibodies, which are thought to be a factor in both serotype-
specific immunity to infection as well as the pathogenesis of
dengue, through a mechanism of antibody-dependent enhance-
ment of infection [4,5].
Previous studies have indicated a low incidence of DENV
exposure in infants [5,6], however infants with DHF can be
clinically challenging to manage and are at higher risk of mortality
than older children [4,7]. In dengue-endemic areas infants under
one year of age comprise between 1–5% of the dengue cases
admitted to hospital each year [4,5], however only a limited
number of studies have documented clinical and laboratory
findings in infants with dengue [8,9]. This evidence indicates that
the clinical manifestations of dengue in infants may differ from
older children and adults, with a greater frequency of low platelet
count (,50000 cells/mm
3), plasma leakage and shock and fewer
haemorrhagic manifestations in infants compared with dengue in
older children [8,9]. This paper describes the clinical, hematolog-
ical and virological characteristics of infants hospitalized with
dengue in southern Vietnam. These characteristics were compared
to infants hospitalized with other acute febrile illnesses.
Methods
Patient recruitment and sample collection
This prospective, descriptive study was conducted at Pediatric
Hospitals Number 1 and Number 2, Ho Chi Minh City, and at
Dong Thap Hospital, Dong Thap province, Vietnam, from
November 2004 to December 2007. Infants under 18 months old
with suspected dengue were eligible to be enrolled. Recruitment
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Number 1 from July to December 2005. Written informed consent
was obtained from a parent or guardian of each patient. The study
was approved by the Scientific and Ethical Committees of the
Hospital for Tropical Diseases, Children’s Hospital No. 1,
Children’s Hospital No. 2, and Dong Thap Hospital and Oxford
Tropical Research Ethical Committee. Daily venous or capillary
blood samples were collected from infants for 4 consecutive days
beginning on entry to the study (study day 0), and again 10–14
days after discharge from hospital. Venous blood samples were
collected from the mothers of each infant on study day 0 and again
4–8 days later. The extent of hemoconcentration during
symptomatic illness was determined by comparing the maximum
hematocrit recorded during hospitalization with either the value
recorded at follow-up in each patient (47% of cases) or at hospital
discharge for those who did not return for follow-up (53% of
cases).
Dengue diagnostics
Dengue antigen capture IgM and IgG ELISA assays used both
inactivated DENV and Japanese encephalitis virus (JEV) antigens
and monoclonal anti-DENV antibody provided by Venture
Technologies (Sarawak, Malaysia) as previously described [10].
Acute DENV infection was defined as DENV-IgM seroconversion
(i.e. from negative to positive) between paired specimens, or rising
levels of DENV reactive IgM (at least 20% increase in DENV-IgM
ELISA Units from 1
st to 2
nd sample and 2
nd sample has $20
ELISA Units). World Health Organization (WHO) classification
criteria for disease severity [11] were applied to each case after
reviewing study notes.
DENV viraemia was measured using an internally-controlled,
serotype-specific, real-time RT-PCR assay [12]. Results were
expressed as cDNA equivalents per milliliter of plasma. DENV
NS1 antigen in plasma was measured using the Platelia NS1 assay
(BioRad, Hercules, CA) according to the manufacturers’ instruc-
tions. The concentration of DENV NS1 protein in test plasma
samples was quantified by reference to a standard curve, using
serial dilutions of immune-affinity purified recombinant DENV-2
NS1 protein (Hawaii Biotechnology Group, Inc). The limit of
detection of this test was 5 ng/ml. DENV viraemia and NS1
antigenaemia were measured in samples collected on four
consecutive days from study enrolment.
Plaque reduction neutralization test (PRNT)
Neutralizing antibody titres against four reference serotypes
(DENV-1 PR/94, DENV-2 NGC, DENV-3 Sleman/76, and
DENV-4 814699) in maternal plasma samples were determined
by a complement-enhanced PRNT assay as described previously
[13].
Statistical analysis
Statistical analyses were performed with SPSS version 14. To
compare the distribution of categorical variables between patient
groups, a chi-squared test for association was used, with p,.05
considered to be statistically significant. For comparison of con-
tinuous variables between groups we used a non-parametric test
(Mann Whitney U) or, wherethere weremore than two comparison
groups, Kruskal-Wallis one-way analysis of variance. We calculated
Spearman’s rank correlation coefficients (rho) to examine the
strength of association between two continuous variables.
Results
Characteristics of the study population
During the study period, we enrolled 293 inpatient infants and
young children with suspected dengue and 10 infants treated as
outpatients. Seventy-five of these infants have been described
previously by our group [13]. The intention of this report is to
summarize the main clinical and virological findings in a larger
population of infants with dengue. Table 1 shows the demographic
characteristics of study participants. Infants’ mothers were aged
between 19–45 years old (median: 28 yrs), and the infants wereaged
between 2–18 months old (median: 7 months). The male to female
Author Summary
Dengue is a major public health problem in tropical and
subtropical countries, including Vietnam. Dengue cases
occur in children and young adults; however, severe
dengue also occurs in infants less than 1 year of age.
Prompt recognition of dengue is important for appropriate
case management, particularly in infants in whom febrile
illness from other causes is common. We describe the
clinical picture, virological and immunological characteris-
tics of infants with dengue admitted to three hospitals in
southern Vietnam, compared with infants admitted with
fever not due to dengue. We show that infants with
dengue are difficult to distinguish from those with other
febrile illnesses based on signs and symptoms at
presentation, and so laboratory tests to confirm dengue
virus infection may be useful for diagnosis and manage-
ment. Conventional diagnostic methods for dengue have
low sensitivity early in infection, and we show that an
alternative antigen-detection assay that has demonstrated
good sensitivity and specificity in older age groups also
performs well in infants. This study will help to inform the
diagnosis and management of dengue in infants.
Table 1. Demographic and serological characteristics of
study participants.
Features
Dengue
(N=204)
OFI
(N=99)
Median maternal age (range) (yrs) 27 (19–44) 29 (20–45)
Infant age ,4m o n t h s 1 1 5
4–10 months 163 72
.10 months 30 22
Sex Male 115 58
Female 86 40
Place of enrolment Ho Chi Minh City 174 66
Dong Thap 30 33
Hospital ward of enrolment Inpatient 194 99
Outpatient 10 0
Median day of illness at enrolment (range) 5 (3–9) 4 (1–7)
Positive DENV reactive IgM at
admission
Yes 165 0
No 35 99
Positive DENV reactive IgG at
discharge
Yes 96 0
No 108 99
Primary/secondary DENV infection Primary 201 N/A
Secondary 3 N/A
doi:10.1371/journal.pntd.0000657.t001
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enrolled on day 4 or 5 of illness. Sixty-eight percent (204/303)
of enrolled infants had serologically confirmed dengue, of which
201 were primary dengue cases and 3 secondary dengue cases.
The remaining 99 patients (32%) without serological evidence of
dengue were classified as ‘‘other febrile illnesses’’ (OFI). Almost
80% (162/204) of the infants with laboratory confirmed dengue
were between 4–10 months old, with the peak at 7–8 months of age.
Clinical characteristics of infants with
laboratory-confirmed dengue
Most of the primary dengue cases were classified as DHF grade
II (141/201; 70%), with 17% (35/201) classified as DF and 9%
(19/201) classified as DSS (DHF III and IV). Five cases could not
be classified by the WHO criteria because of insufficient
investigations of vascular leakage. Clinical data was not available
for one infant. The five infants in whom disease severity could not
be classified were excluded from further analysis.
The clinical features of participants at the time of enrolment are
shown in Table 2. Infants with dengue did not present with
specific clinical signs compared to patients with other febrile
illnesses (OFI). Common features of upper respiratory tract viral
infection, including running nose and cough, were observed with
similar frequency in both groups, however diarrhea, vomiting and
a petechial rash occurred more frequently in dengue patients than
in infants with OFI. Fever was observed less frequently in dengue
patients; however in some patients enrolled later in their illness,
defervescence may have occurred prior to study enrolment.
The hematological findings and clinical manifestations during
hospitalization in infants with primary dengue or other febrile
illness are shown in Table 3 and Table 4. The median nadir in
white blood cell (WBC) count in infants with dengue was
significantly lower than that in infants with OFI (5600 vs
6100 cells/mm
3, P=0.035) and was primarily due to neutropenia.
Liver transaminase levels were significantly higher in dengue cases
(Table 3). In comparison with OFI cases, infants with dengue had
lower platelet nadirs, greater hemoconcentration, petechiae,
bruising, hepatomegaly and clinical evidence of systemic vascular
leak (Table 4). The case fatality ratio was approximately 1%
among dengue cases. One patient in the OFI group had shock and
died of meningitis and pneumonia (Table 4).
Virological characteristics of infants with primary dengue
RT-PCR was performed on plasma samples collected at
enrolment. In plasma samples from the 201 serologically-
confirmed primary dengue patients, DENV was detected in 161
(80%). All four serotypes were detected: DENV-1 (66/161, 41%),
DENV-2 (72/161, 44%), DENV-3 (22/161, 14%), and DENV-4
(2/161, 1%) (Table 5). The remaining 40/201 (20%) cases were
aviraemic at the time of study entry. DENV-1 and DENV-2 were
the dominant serotypes in this study population and accounted for
85% (137/161) of viraemic patients.
We compared disease severity in dengue patients infected
with different DENV serotypes (Table 5). Although a greater
proportion of DENV-2 infections resulted in DHF/DSS (91%)
compared to the other serotypes (DENV-1 78%, p=0.03; DENV-
3 82%, p=0.20; DENV-4 50%, p=0.05), overall there was no
significant association between DENV serotype and severity of
disease when DHF and DSS were considered separately (p=0.22).
Four of the 134 infants who developed DHF/DSS were aviraemic
at admission. Data on viraemia at enrolment was available for
118/201 infants with primary dengue. We compared viraemia at
the time of study enrolment in infants with DF, DHF and DSS and
found a non-significant trend towards higher viraemia with more
severe disease (p=0.1; Table 5). However, a limitation of our
study was that we did not have samples collected in the first
Table 2. Clinical symptoms in dengue and non-dengue
patients at the time of study enrolment.
Symptoms
Percent of patients presenting with each
symptom P value*
Primary dengue
(N=201)
Other febrile illness
(N=99)
%
Missing
data %
Missing
data
Fever 83 1 94 0 0.03
Diarrhea 43 1 29 1 0.05
Running nose 37 1 37 0 0.74
Cough 56 3 46 0 0.17
Vomiting 57 4 31 1 ,0.01
Jaundice 1 12 0 3 0.34
Petechial Rash 34 3 19 3 0.02
CNS sign 4 11 6 1 0.12
*:Cross tabulation, Chi-square Test.
doi:10.1371/journal.pntd.0000657.t002
Table 3. Hematological findings in infants during hospitalization and at follow-up.
Median (5
th-95
th percentile)
P value
(dengue vs OFI)
P value
(dengue vs follow-up)
Dengue OFI Follow-up
WBC
a (cells/mm
3) 5600 (1170–21400) 6100 (1630–21600) 9260 (5590–21600) 0.04 ,0.001
Lymphocyte
a (%) 67% (39–83) 59% (31–82) 62% (42–74) 0.001 ,0.001
Neutrophil
a (%) 23% (7–53) 29% (7–64) 27% (16–46) ,0.001 0.01
Monocyte
a (%) 12% (2–25) 13% (2–32) 8% (3–13) 0.3 ,0.001
AST
b (UI/ml) 152 (13–2105) 51 (6–186) N/A ,0.001 N/A
ALT
b (UI/ml) 57 (14–975) 26 (6–89) N/A ,0.001 N/A
Platelet nadir cells/mm
3 32000 (13100–92000) 96500 (12000–281000) N/A ,0.001 N/A
a: minimum values measured in 163/72/72 infants with dengue/with OFI/at follow-up, respectively.
b: maximum values, of 56/62 infants with dengue/OFI, respectively.
doi:10.1371/journal.pntd.0000657.t003
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Instead, we were limited to measuring viraemia at a time when in
most patients it was already declining.
The concentration (ng/ml) of DENV NS1 antigen in infant
plasma was measured at study enrolment (Table 5). At enrolment,
176/196 (89%) of dengue cases had detectable plasma NS1 levels.
The NS1 concentration was significantly higher in DENV-1 and
DENV-3 infections than in DENV-2 infections (p,0.001), and did
not correlate with viraemia levels, which were similar among
DENV serotypes (data not shown). We compared NS1 levels
between primary dengue patients of different severities, stratified
by DENV serotype (Figure 1). This showed a non-significant trend
toward higher NS1 levels with increasing disease severity in those
infants infected with DENV-3 or avireamic at admission (Chi-
square test: p=0.2, p=0.1 respectively), but this trend was not
observed in DENV-1 and DENV-2 infected patients.
The sensitivity of dengue diagnostic tests in acute illness
The sensitivity of different dengue diagnostic approaches at
the time of enrolment were compared to laboratory confirmation
by serology on paired samples. NS1 detection was a sensitive
approach (.80%) to diagnosing dengue in enrolment plasma
samples collected on day 3, 4 or 5 of illness (Figure 2). The
sensitivity of the NS1 test was significantly higher than real time
RT-PCR in the first 6 days of illness (Chi-square test: p=0.001).
RT-PCR was sensitive early, but sensitivity declined with
increasing illness duration. Conversely, IgM detection by MAC
ELISA was only moderately sensitive on day 3 and 4, but
detection improved with increasing duration of illness.
DENV neutralizing antibodies in maternal blood and
relationship with age of disease onset
Plasma samples from 120 mothers of infants with primary
dengue were available for PRNT50 assays, after excluding those
women with serological evidence of recent DENV infection
(n=33), those with preterm babies (n=19) and those mothers who
did not provide paired blood samples (n=29). Recent DENV
infection was defined as a four-fold change in IgG to recombinant
E protein in paired plasma samples or when any maternal plasma
sample was IgM positive. Amongst the evaluated maternal plasma
samples, 100% had neutralizing antibodies (PRNT50 assay) to
at least one DENV serotype and 96% of mothers possessed
neutralizing antibodies to $3 serotypes. The median titer of
neutralizing antibody against DENV-4 was much lower than to
the other 3 serotypes. The maternal neutralizing antibody titre to
DENV1-4 was independent of maternal age (data not shown).
Table 4. Clinical and haematological characteristics of infants with acute febrile illness.
Disease groups [number (%)/median (5
th-95
th percentile)]
Features DF (N=35) DHF (N=141) DSS (N=19) OFI (N=99) P value
c
Day of illness at enrolment 4 (3–6) 5 (3–6) 5 (3–6) 4 (2–6) ,0.001
Hepatomegaly 27 (79%) 133 (93%) 19 (100%) 51 (52%) ,0.001
Petechiae 32 (94%) 141 (99%) 19 (100%) 81 (82%) ,0.001
Bleeding
a 0 11 (5%) 5 (26%) 7 (7%) 0.10
Bruising 4 (11%) 60 (42%) 10 (53%) 4 (4%) ,0.001
Maximum hemoconcentration (%) 4 [(-8)-16] 23 [8–42] 33 [17–50] 9 [(-8)-27] ,0.001
Clinical leak
b 0 51 (36%) 10 (53%) 0 ,0.001
Cardiovascular shock 0 0 19 (100%) 2 (2%) 0.01
Blood transfusion 0 1 (0.7%) 6 (32%) 1(1%) 0.16
Death 0 0 2 (10%) 1 (1%) 0.36
aGum, nose or gastrointestinal bleeding;
bClinical evidence of leak revealed by ultrasound or chest X-ray; (pleural effusions, ascites, gall bladder);
cdifferences between Dengue group and OFI group tested by cross tabular Chi square test or Mann-Whitney U.
doi:10.1371/journal.pntd.0000657.t004
Table 5. Virological characteristics at enrolment in infants with dengue.
DF
(N=35)
DHF
(N=141)
DSS
(N=19)
Not classifiable
(N=5)
Serotype subtotal
(% of total)
Day of illness at enrolment 4 (3–8) 5 (3–9) 5 (3–7) 5 (4–8)
DENV-1 14 42 8 2 66 (41.5%)
DENV-2 6 59 5 1 71 (43.4%)
DENV-3 4 16 2 0 22 (13.8%)
D E N V - 4 1100 2 ( 1 . 3 % )
Aviremic 10 23 4 2
Median (range) viraemia on enrolment (log copies/ml) 4.6 (3.4–8.1) 4.7 (3.4–8.5) 5.1 (3.4–8.5) 4.2 (3.6–4.8)
Median (range) NS1 antigenaemia on enrolment (log ng/ml) 2.6 (0.8–3.4) 2.5 (0.7–3.9) 2.8 (1.3–3.6) 2.6 (0.8–2.7)
doi:10.1371/journal.pntd.0000657.t005
Dengue in Infants
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infected each infant were compared to the infant’s age at illness
onset. There was only a limited correlation between maternal
neutralizing antibody titres and the age at which infants present to
hospital with symptomatic primary dengue (Figure S1).
Discussion
This study describes the clinical and virological features of
dengue in Vietnamese infants and is an extension of previous
reports from our group [13]. This report highlights the value of
NS1 detection in the diagnosis of dengue in infants who otherwise
present with non-specific clinical symptoms. Interestingly, we
found DENV-2 infections to be associated with significantly lower
plasma NS1 levels relative to DENV-1 or DENV-3 infections.
Collectively, these data provide new insights into the pathogenesis
of severe dengue in an age-group where diagnosis and manage-
ment can be challenging.
The majority of infants hospitalized with dengue were between
four and ten months of age and this is consistent with previous
studies at this hospital and elsewhere in SE Asia [4,5,8]. Infants
with dengue initially presented with non-specific symptoms that
included coryza, cough and diarrhea. Subsequently, many infants
developed pathognomonic signs of DHF including petechiae,
bleeding, bruising and vascular leak. Although the World Health
Organization classification criteria were originally developed for
older children, 97% of the infants with acute dengue in this study
were adequately classified [11]. Consistent with previous studies
[8,9], we demonstrate that DHF/DSS can occur during primary
infection of infants. Surprisingly, the patients enrolled in our study
had predominantly DHF grade II, with few cases having either DF
or DSS. Consequently, we had little statistical power to detect
differences in clinical or virological features between mild and
severe cases. The limited breadth in our patient population was
despite efforts to recruit patients with milder disease presentations
by enrolling infants in the outpatients department of Children’s
Hospital No. 1.
The clinical signs and hematological manifestations in infants
hospitalized with dengue were similar to those seen in children and
adults [8,9,14,15]. Whole blood count results during hospitaliza-
tion demonstrated leucopenia and elevated liver transaminases in
infants with dengue compared to those with other febrile illnesses,
however these differences are unlikely to be sufficient for
differential diagnosis at the individual level. Infants with dengue
were more likely to have hepatomegaly, petechiae and bruising
than infants with other febrile illnesses. Clinical evidence of
plasma leak (e.g. ascites) was observed in a minority of infants with
DHF/DSS.
The average time to study enrolment since illness onset was 4–5
days. A disadvantage of not enrolling patients into the study earlier
in their illness is that it was not possible to identify early risk factors
for more severe outcomes e.g. DSS. One of the reasons few infants
were enrolled into the study early in their illness relates to the
standard of care at the hospitals where the study was conducted.
Infants with fevers of just 1–2 days duration are often seen in the
outpatient department, but most are treated as outpatients only
with daily follow-up. For infants with DHF, only when the
characteristic thrombocytopenia and a rising hematocrit are
observed, usually on day 3 or 4, are those infants admitted to
hospital. Specific dengue diagnostic tests such as PCR or NS1
assays are not routinely available.
By RT-PCR we were able to detect viraemia in 80% of the
dengue cases. As supported by previous studies [16], we also found
that the proportion of viraemic cases was highest in the first few
days of illness. In this study, neither the viraemia nor antigenemia
at enrolment correlated with disease severity, although a trend
towards higher NS1 concentrations with increasing disease
Figure 1. NS1 antigenaemia by disease severity. Shown are the
median, interquartile and 95
th-percentile ranges of log10 NS1 concentra-
tion at enrolment, distributed by DENV serotypes and disease severity.
Day of illness ranged from 3–9 and was comparable among DF, DHF, DSS
groups. The number of patients in each group is shown in italics.
doi:10.1371/journal.pntd.0000657.g001
Figure 2. The sensitivity of diagnostic tests in acute DENV infection of infants. The number of patients evaluated on each day of illness is
shown below the graph. Bars show the percentage of samples positive by each assay.
doi:10.1371/journal.pntd.0000657.g002
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aviraemic at admission. However, our study participants were
generally enrolled after 4–5 days of illness and therefore we
probably have not measured the peak viraemia or NS1
antigenaemia. A greater proportion of DENV-2 infections resulted
in DHF/DSS compared to other serotypes, however the number
of DF and DSS cases was small and there was no significant
association overall between infecting serotype and disease severity.
NS1 detection may be helpful in diagnosing dengue [17,18,19,20].
In this paper, we illustrated the superior sensitivity of DENV NS1
detection incomparisonwithtwoother dengue diagnostic tests(MAC
ELISA and real-time RT-PCR), especially in the first few days
after disease onset (#4 days). Early diagnosis could assist clinical
management by focusing attention on the clinically important
features of dengue (capillary leakage) and minimizing unnecessary
use of antibiotics. The sensitivity of NS1 detection was higher than
RT-PCR during the first six days of illness, and many infants were
still NS1 positive at the time of discharge from hospital. This is
consistent with previous descriptions of the sensitivity of NS1
detection in children and adults with primary dengue [17,20,21].
One of the reasons NS1 detection might be more sensitive in
primary dengue is that the IgM/IgG response does not become
measurable until day 6 or later. Previous studies in Vietnamese
children demonstrated that a measurable anti-DENV IgG level in
thetest samplesignificantly reduced the likelihood of NS1 detection,
possibly because of the immune complex formation between anti-
NS1 IgG and soluble NS1 in the blood [20]. Viraemia and NS1
antigenaemia appear to correlate closely early in infection, with
divergence in the sensitivity of NS1 detection and RT-PCR from
day four of illness (Figure 2). This may be due to more rapid
degradation of viral RNA compared to NS1 protein. Our results
support previous findings [20] of a lower concentration of NS1
antigen in DENV-2 infections, compared with other serotypes, and
demonstratethatthisisobservedalsoinprimaryinfectionsininfants
as well as in secondary infections, with which DENV-2 is commonly
associated. This could be due to the antibodies used in the NS1
ELISA having differential binding to DENV-2 NS1 protein
compared with other serotypes and the limitation of using a
DENV-2 NS1 protein standard for calibration of the quantitative
assay used for all serotypes. This may have resulted in an
overestimate of NS1 levels for DENV-1 and DENV-3, however
our analysis of the association between NS1 antigenaemia and
disease severity was stratified by serotype so is robust to this
limitation. Alternatively, DENV-2 infections may result in less
soluble NS1 protein due either to a greater tendency for immune
complex formation with pre-existing IgG or to differences in viral
infection between serotypes.
All of the mothers of infants with primary dengue in this study
for whom plasma samples were available possessed DENV-
neutralizing antibody, as measured by PRNT50. Neutralizing
antibody, acquired passively by infants born to dengue-immune
mothers, is suggested to provide protective immunity against
dengue during the early months of life, but sub-neutralizing levels
of maternal antibody are thought to be a factor in the pathogenesis
of dengue in infants [22]. We have recently demonstrated that the
waning of maternal DENV-neutralizing antibody correlates
temporally with the age of peak dengue burden in infants [23].
Building on previous analyses [13] in a small subset of the current
study population, we examined the relationship between maternal
serotype-specific neutralizing antibody titre and infants’ age at
infection in individual mother-infant pairs, with the hypothesis
that a higher PRNT50 titre in the mother may confer a longer
period of protection in the infant. A weak positive correlation
between maternal anti-DENV-2 PRNT50 titre and age at time of
disease onset in infants with DENV-2 infections suggested higher
maternal neutralizing antibody titres may be associated with a
longer window of passively acquired immunity for DENV-2.
However, no such correlation was found for DENV-1 or DENV-
3. Our findings differ from recently reported observations of a
strong positive correlation between maternal DENV-3 PRNT50
titre and infant age at the time of symptomatic DENV-3 infection
[24]. This difference may be partially attributable to several
limitations to the current analysis. Maternal blood at infant
admission is an imperfect proxy for infant’s maternal antibody titre
at birth as, although we excluded any mothers with serological
evidence of recent dengue infection, we cannot exclude the
possibility of DENV exposure and antibody boosting in the
mothers since birth. For reasons of feasibility, and consistent with
the work of others [24], we measured PRNT50 titres using
prototype dengue viruses from each serotype, not viruses isolated
from individual infected infants. Although these titres may
therefore be an imperfect measure of in vivo DENV neutralizing
capacity, we believe this to be a reasonable methodology based on
the amino acid identity of the DENV E gene between the
prototype viruses and dengue viruses isolated in southern Vietnam
during the study period (mean 97.8% identity, range 96.3%–
98.5% comparing prototype DENV of each serotype to 4
contemporary isolates of that serotype). An important consider-
ation is the fact that the large majority (73%) of dengue cases in
our study occurred after 6 months of age. We have reported
previously that maternal dengue neutralizing antibody was
undetectable (by PRNT50) in the majority of a healthy cohort of
Vietnamese infants by 6 months of age, regardless of titre at birth
[23]. This suggests that after 6 months, infant age at dengue onset
may be independent of PRNT50 titre at birth if few or no infants
have remaining protection from maternal antibody. Further
prospective studies of the relationship between passively acquired
antibody and the spectrum of dengue infection and disease in
infants can contribute to an improved understanding of immune
correlates of protection against dengue, and a large prospective
birth cohort study is currently underway in southern Vietnam to
address these questions.
The data presented in this study highlight the challenges faced
by clinicians in distinguishing infants with dengue from those with
other febrile illnesses based on clinical and hematological signs
alone, and thus identifying infants who may be at risk of
developing severe dengue disease. Routine serology is an imperfect
tool for the laboratory confirmation of dengue, particularly in the
first 1–3 days of illness, and our results indicate that the addition of
NS1 detection to the diagnostic algorithm has the potential to
improve the early diagnosis of dengue in infants, as well as in older
children and adults.
Supporting Information
Figure S1 Maternal neutralizing antibody and infant age at
dengue disease onset. Shown is the serotype-specific 50% plaque-
reduction neutralization test (PRNT50) titre in maternal plasma
versus the age of individual infants with primary infection with A)
DENV-2 (N=39), B) DENV-1 (N=38), or C) DENV-3 (N=14).
Each point represents the titre of one mother-infant pair. Only
maternal titres to DENV-2 were positively correlated with infant
age (Spearman’s rho=0.3 (p=0.03)).
Found at: doi:10.1371/journal.pntd.0000657.s001 (0.46 MB TIF)
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